The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors

References

• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54
   PubMed Web of Science ®Google Scholar
• Preto A, Figueiredo J, Velho S, et al. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF (V600E) but not KRAS mutations. J Pathol 2008;214:320-7
   PubMed Web of Science ®Google Scholar
• Erhardt P, Schremser EJ, Cooper GM. BRAF inhibit programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 1999;19:5308-15
   PubMed Web of Science ®Google Scholar
• Campbell SL, Khosravi-Far R, Rossman KL, et al. Increasing complexity of RAS signaling. Oncogene 1998;17:1395-43
   PubMed Web of Science ®Google Scholar
• Marshall CJ. RAS effectors. Curr Opin Cell Biol 1996;8:197-204
   PubMed Web of Science ®Google Scholar
• Rajagopalan H, Bardelli A, Legauer C, et al. Tumorigenesis:RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934
   PubMed Web of Science ®Google Scholar
• Bhatt KV, Spofford LS, Aram G, et al. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 2005;24:3459-71
   PubMed Web of Science ®Google Scholar
• Bhatt KV, Hu R, Spofford LS, et al. Mutant BRAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells. Oncogene 2007;26:1056-66
   PubMed Web of Science ®Google Scholar
• Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-16
   PubMed Web of Science ®Google Scholar
• Aaltonen LA, Peltomaki P, Mecklin JP, et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 1994;54:1645-8
   PubMed Web of Science ®Google Scholar
• Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-19
   PubMed Web of Science ®Google Scholar
• Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75:1215-25
   PubMed Web of Science ®Google Scholar
• Peltomaki PT. Genetic basis of hereditary nonpolyposis colorectal carcinoma (HNPCC). Ann Med 1994;26:215-19
   PubMed Web of Science ®Google Scholar
• Kane MF, Loda M, Gaida GM, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57:808-11
   PubMed Web of Science ®Google Scholar
• Cunningham JM, Christensen ER, Tester DJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998;58:3455-60
   PubMed Web of Science ®Google Scholar
• Cunningham JM, Kim CY, Christensen ER, et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 2001;69:780-90
   PubMed Web of Science ®Google Scholar
• Thibodeau SN, French AJ, Cunningham JM, et al. Microsatellite instability in colorectal cancer:different mutator phenotypes and the principal involvement of hMLH1. Cancer Res 1998;58:1713-18
   PubMed Web of Science ®Google Scholar
• Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011;122:11-19
   PubMed Web of Science ®Google Scholar
• Toon CW, Walsh MD, Chou A, et al. BRAF V600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol 2013;37:1592-602
   PubMed Web of Science ®Google Scholar
• Thiel A, Heinonen M, Kantonen J, et al. BRAF mutation in sporadic colorectal cancer and Lynch syndrome. Virchows Arch 2013;463(5):613-21
   PubMed Web of Science ®Google Scholar
• Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063-9
   PubMed Web of Science ®Google Scholar
• Roskoski R. Jr. RAF protein-serine/threonine kinases:structure and regulation. Biochem Biophys Res Commun 2010;399:313-17
   PubMed Web of Science ®Google Scholar
• Saridaki Z, Papadatos-Pastos D, Tzardi M, et al. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome. Br J Cancer 2010;102:1762-8
   PubMed Web of Science ®Google Scholar
• Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466-74
   PubMed Web of Science ®Google Scholar
• Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer:results from intergroup trial CALGB 89803. Clin Cancer Res 2012;18:890-900
   PubMed Web of Science ®Google Scholar
• Pai RK, Jayachandran P, Koong AC, et al. BRAF mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol 2012;36:744-52
   PubMed Web of Science ®Google Scholar
• Eklöf V, Wikberg ML, Edin S, et al. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer 2013;108:2153-63
   PubMed Web of Science ®Google Scholar
• Peeters M, Oliner K, Parker A, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase 3 study of metastatic colorectal cancer. Clin Cancer Res 2013;19:1902-12
   PubMed Web of Science ®Google Scholar
• Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013;105:1151-6
   PubMedGoogle Scholar
• Wang L, Cunningham JM, Winters JL, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003;63:5209-12
   PubMed Web of Science ®Google Scholar
• Kalady MF, Dejulius KL, Sanchez JA, et al. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum 2012;55:128-33
   PubMed Web of Science ®Google Scholar
• Clancy C, Burke JP, Kalady MF, et al. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. Colorectal Dis 2013;15:711-18
   PubMed Web of Science ®Google Scholar
• Tie J, Gibbs P, Lipton L, et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 2011;128:2075-84
   PubMed Web of Science ®Google Scholar
• Saridaki Z, Tzardi M, Sfakianaki M, et al. BRAF V600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients’ outcome. PLoS One 2013;8:e84604
   PubMed Web of Science ®Google Scholar
• Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011;117:4623-32
   PubMed Web of Science ®Google Scholar
• Artale S, Sartore-Bianchi A, Veronese SM, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008;26:4217-19
   PubMed Web of Science ®Google Scholar
• Italiano A, Hostein I, Soubeyran I, et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 2010;17:1429-34
   PubMed Web of Science ®Google Scholar
• Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790-9
   PubMed Web of Science ®Google Scholar
• Park JH, Han SW, Oh DY, et al. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol 2011;68:1045-55
   PubMed Web of Science ®Google Scholar
• Baas JM, Krens LL, Guchelaar HJ, et al. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist 2011;16:1239-49
   Google Scholar
• Santini D, Spoto C, Loupakis F, et al. High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. Ann Oncol 2010;21:1565
   Google Scholar
• Kopetz S, Overman JM, Chen K, et al. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32:5s
   Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra224
   Web of Science ®Google Scholar
• Spindler KL, Pallisgaard N, Andersen RF, et al. Changes in mutational status during third-line treatment for metastatic colorectal cancer-results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int Journal of Cancer 2014;135:2215-22
   PubMed Web of Science ®Google Scholar
• Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009;361:98-9
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12
   PubMed Web of Science ®Google Scholar
• Raoul JL, Van Laethem JL, Peeters M, et al. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer 2009;9:112
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Van Cutsem E, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012;48:1466-75
   PubMed Web of Science ®Google Scholar
• De Roock W, De Vriendt V, Normanno N, et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011;12:594-603
   PubMed Web of Science ®Google Scholar
• Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. Eur J Cancer 2015;51(15):587-94
   Google Scholar
• Wang Q, Hu WG, Song QB, Wei J. BRAF V600E mutation as a predictive factor of anti-EGFR monoclonal antibodies therapeutic effects in metastatic colorectal cancer: a meta-analysis. Chin Med Sci J 2014;29:197-203
   PubMedGoogle Scholar
• Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25:1346-55
   PubMed Web of Science ®Google Scholar
• Di Bartolomeo M, Pietrantonio F, Perrone F, et al. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. Target Oncol 2014;9:155-62
   Google Scholar
• Seymour MT, Brown SR, Middleton G, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013;14:749-59
   PubMed Web of Science ®Google Scholar
• Therkildsen C, Bergmann TK, Henrichsen-Schnack T, et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol 2014;53:852-64
   PubMed Web of Science ®Google Scholar
• Teng HW, Huang YC, Lin JK, et al. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol 2012;106:123-9
   Google Scholar
• Karagkounis G, Torbenson MS, Daniel HD, et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer 2013;119:4137-44
   PubMed Web of Science ®Google Scholar
• Renaud S, Romain B, Falcoz PE, et al. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. Br J Cancer 2015;112:720-8
   PubMed Web of Science ®Google Scholar
• Giampieri R, Aprile G, Del Prete M, et al. Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients. Curr Drug Targets 2014;15:1225-30
   PubMed Web of Science ®Google Scholar
• Giampieri R, Scartozzi M, Del Prete M, et al. The “angiogenetic ladder”, step-wise angiogenesis inhibition in metastatic colorectal cancer. Cancer Treat Rev 2014;40:934-41
   Google Scholar
• Giampieri R, Scartozzi M, Del Prete M, et al. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. Crit Rev Oncol Hematol 2013;88:272-83
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29(15):2011-19
   PubMed Web of Science ®Google Scholar
• Souglakos J, Philips J, Wang R, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009;101:465-72
   PubMed Web of Science ®Google Scholar
• Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360(6):563-72
   PubMed Web of Science ®Google Scholar
• Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009;27(35):5931-7
   PubMed Web of Science ®Google Scholar
• Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014;371:1609-18
   PubMed Web of Science ®Google Scholar
• Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52
   PubMed Web of Science ®Google Scholar
• Loupakis F, Cremolini C, Salvatore L, et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 2014;50:57-63
   PubMed Web of Science ®Google Scholar
• Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065-75
   PubMed Web of Science ®Google Scholar
• Wan PT, Garnett MJ, Roe SM, et al. Mechanism of action of the RAF-ERK signaling pathway by oncogenic mutations of BRAF. Cell 2004;116:855-67
   PubMed Web of Science ®Google Scholar
• Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF mutant melanoma. Nature 2010;467:596-9
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19
   PubMed Web of Science ®Google Scholar
• Yang H, Higgins B, Kolinsky K, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 2012;72:779-89
   PubMed Web of Science ®Google Scholar
• Kopetz S, Desai J, Chan E, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 2010;28:15s
   PubMedGoogle Scholar
• Corcoran RB, Falchook GS, Infante JR, et al. Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis. J Clin Oncol 2014;32(Suppl):abstr. 3517
   Google Scholar
• Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2011;483:100-3
   Google Scholar
• Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012;2:227-35
   PubMed Web of Science ®Google Scholar
• Ahronian LG, Sennott EM, VAN Allen EM, et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov 2015. [Epub ahead of print]
   Google Scholar
• Bendell JC, Atreya C, André T, et al. Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). J Clin Oncol 2014;32:5s
   Google Scholar
• Ahmed D, Eide PW, Eilersen DA, et al. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2013;2:e71
   PubMed Web of Science ®Google Scholar
• Oikonomou E, Koc M, Sourkova V, et al. Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PLoS ONE 2011;6:21632
   PubMed Web of Science ®Google Scholar
• Mao M, Tian F, Mariadason JM, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Cancer Res 2013;19:657-67
   Google Scholar
• Van Geel R, Elez E, Bendell JC, et al. Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer. J Clin Oncol 2014;32:5s
   Google Scholar
• Hong DS, Morris VK, Fu S, et al. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. J Clin Oncol 2014;32:5s
   Google Scholar
• Kopetz S, McDonough S, Morris VK, et al. S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC). J Clin Oncol 2015;33(Suppl 3):abstr TPS790
   Google Scholar
• Yaeger R, Cercek A, O’Reilly EM, et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res 2015;21:1313-20
   PubMed Web of Science ®Google Scholar